NXI Therapeutics AG

NXI Therapeutics AG is a Swiss biotechnology company founded in 2021 as a spin-off from the Biozentrum at the University of Basel. The company is dedicated to developing selective immunomodulators that target the coronin 1 pathway to treat autoimmune diseases and support organ transplantation. By modulating coronin 1, these therapeutic candidates aim to selectively inhibit T cell immune responses involved in graft rejection and autoimmunity while maintaining the body’s protective immunocompetence against infections and cancer, distinguishing them from traditional, non-selective immunosuppressants.

This approach addresses a significant clinical need, as patients currently relying on conventional immunosuppressive therapies often face severe side effects due to the broad, non-selective nature of these drugs. NXI Therapeutics is focused on advancing its proprietary modulators through preclinical development, including identifying orally bioavailable compounds and developing formulations for topical use. Supported by grants and pre-seed financing, the company continues to validate its technology in preclinical models of alloimmunity, psoriasis, inflammatory bowel disease, and graft-versus-host disease.